LVGN-3036

N/A

Report date: 2022/01/21 15:33:40

Base Information

Drug NameLVGN-3036

Drug Alias NameLVGN-3036

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionProgrammed death-ligand 1 blockersTumor necrosis factor receptor superfamily member 5 inhibitors

TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 5

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLijin Biotechnology (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesLijin Biotechnology (Shanghai) Co Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A